P16 Antibody [5A8A4 / 3G8D12] | 32-172

P16 Antibody [5A8A4 / 3G8D12] | 32-172 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Homology: N/A

Immunogen: Ni-NTA purified truncated recombinant P16 expressed in E. Coli strain BL21 (DE3) .

Research Area: Other

Tested Application: E, WB, IHC

Application: Western Blot:1:500 - 1:2, 000
IHC (P) :1:200 - 1:1, 000
ELISA:Propose dilution 1:10, 000.
Determining optimal working dilutions by titration test.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: N/A

Clonality: Monoclonal

Clone: 5A8A4 / 3G8D12

Isotype: N/A

Conjugate: Unconjugated

Physical State: N/A

Buffer: Ascitic fluid containing 0.03% sodium azide.

Concentration: N/A

Storage Condition: Human P16 monoclonal antibody can be stored at -20˚C, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: ARF, MLM, P14, P16, P19, CMM2, INK4, MTS1, TP16, CDK4I, CDKN2, INK4A, MTS-1, P14ARF, P19ARF, P16INK4, P16INK4A, P16-INK4A

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: p16 (cyclin-dependent kinase inhibitor 2A, INK4a) is a tumor suppressor protein. It is a specific inhibitor of Cdk 4 / Cdk 6, and a tumor suppressor involved in the pathogenesis of a variety of malignancies. Recent analyses of the p16 INK4a gene revealed homozygous deletions, nonsense, missense, or frameshift mutations in several human cancers. Although the frequency of p16 INK4a abnormalities is higher in tumor derived cell lines than in unselected primary tumors, significant subsets of clinical cases with aberrant p16 INK4a gene have been reported among melanomas, gliomas, esophageal, pancreatic, lung, and urinary bladder carcinomas, and some types of leukemia.